iScience (Feb 2024)

Borrelia-specific antibody profiles and complement deposition in joint fluid distinguish antibiotic-refractory from -responsive Lyme arthritis

  • Kathryn A. Bowman,
  • Christine D. Wiggins,
  • Elizabeth DeRiso,
  • Steffan Paul,
  • Klemen Strle,
  • John A. Branda,
  • Allen C. Steere,
  • Douglas A. Lauffenburger,
  • Galit Alter

Journal volume & issue
Vol. 27, no. 2
p. 108804

Abstract

Read online

Summary: Lyme arthritis, caused by the spirochete Borrelia burgdorferi, is the most common feature of late disseminated Lyme disease in the United States. While most Lyme arthritis resolves with antibiotics, termed “antibiotic-responsive”, some individuals develop progressive synovitis despite antibiotic therapy, called “antibiotic-refractory” Lyme arthritis (LA). The primary drivers behind antibiotic-refractory arthritis remain incompletely understood. We performed a matched, cross-compartmental comparison of antibody profiles from blood and joint fluid of individuals with antibiotic-responsive (n = 11) or antibiotic-refractory LA (n = 31). While serum antibody profiles poorly discriminated responsive from refractory patients, a discrete profile of B.burgdorferi-specific antibodies in joint fluid discriminated antibiotic-responsive from refractory LA. Cross-compartmental comparison of antibody glycosylation, IgA1, and antibody-dependent complement deposition (ADCD) revealed more poorly coordinated humoral responses and increased ADCD in refractory disease. These data reveal B.burgdorferi-specific serological markers that may support early stratification and clinical management, and point to antibody-dependent complement activation as a key mechanism underlying persistent disease.

Keywords